MX2020014031A - Proteinas heterodimericas y usos de las mismas. - Google Patents
Proteinas heterodimericas y usos de las mismas.Info
- Publication number
- MX2020014031A MX2020014031A MX2020014031A MX2020014031A MX2020014031A MX 2020014031 A MX2020014031 A MX 2020014031A MX 2020014031 A MX2020014031 A MX 2020014031A MX 2020014031 A MX2020014031 A MX 2020014031A MX 2020014031 A MX2020014031 A MX 2020014031A
- Authority
- MX
- Mexico
- Prior art keywords
- heterodimeric proteins
- proteins
- immunotherapies
- autoimmunity
- cancer
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000005784 autoimmunity Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862688167P | 2018-06-21 | 2018-06-21 | |
| US201862703248P | 2018-07-25 | 2018-07-25 | |
| PCT/US2019/038451 WO2019246508A1 (en) | 2018-06-21 | 2019-06-21 | Heterodimeric proteins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020014031A true MX2020014031A (es) | 2021-05-12 |
Family
ID=68983045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020014031A MX2020014031A (es) | 2018-06-21 | 2019-06-21 | Proteinas heterodimericas y usos de las mismas. |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10995127B2 (https=) |
| EP (1) | EP3810172A4 (https=) |
| JP (3) | JP7439372B2 (https=) |
| KR (1) | KR20210025054A (https=) |
| CN (1) | CN112566650A (https=) |
| AU (1) | AU2019290192A1 (https=) |
| BR (1) | BR112020026112A2 (https=) |
| CA (1) | CA3103975A1 (https=) |
| MX (1) | MX2020014031A (https=) |
| WO (1) | WO2019246508A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210025054A (ko) * | 2018-06-21 | 2021-03-08 | 샤턱 랩스 인코포레이티드 | 이형이량체 단백질 및 이의 용도 |
| AU2020340424A1 (en) * | 2019-08-30 | 2022-03-31 | Shattuck Labs, Inc. | Chimeric proteins in autoimmunity |
| WO2021202354A1 (en) * | 2020-03-30 | 2021-10-07 | Proviva Therapeutics (Hong Kong) Limited | Il-2/il-15 compositions and methods of use thereof |
| US12012441B2 (en) | 2020-10-26 | 2024-06-18 | Neptune Biosciences Llc | Engineered human IL-21 cytokines and methods for using the same |
| WO2022241058A1 (en) | 2021-05-12 | 2022-11-17 | Applied Biomedical Science Institute | Methods of screening and expression of disulfide-bonded binding polypeptides |
| US20240262893A1 (en) | 2021-05-12 | 2024-08-08 | Applied Biomedical Science Institute | Binding polypeptides against sars cov-2 and uses thereof |
| WO2023205738A2 (en) * | 2022-04-20 | 2023-10-26 | Neptune Biosciences Llc | Orthogonal il-21 receptor/cytokine systems |
| CA3256783A1 (en) | 2022-05-16 | 2023-11-23 | Enkefalos Biosciences, Llc | Blood-brain barrier translocation peptides and associated molecules and their methods of use |
| WO2024019984A1 (en) * | 2022-07-18 | 2024-01-25 | Cargo Therapeutics, Inc. | Cytokine receptor switch polypeptides and uses thereof |
| EP4619430A1 (en) | 2022-11-16 | 2025-09-24 | Applied Biomedical Science Institute | Fusion polypeptides and binding peptides and methods for producing and using same |
| WO2024123812A1 (en) | 2022-12-05 | 2024-06-13 | Shattuck Labs, Inc. | Fusion proteins for the treatment of cardiometabolic diseases |
| WO2025133115A1 (en) * | 2023-12-21 | 2025-06-26 | Ose Immunotherapeutics | Lipid-based nanoparticles comprising il-35 |
| WO2025140436A1 (zh) * | 2023-12-27 | 2025-07-03 | 上海药明生物技术有限公司 | 重组il-27蛋白及其制备方法 |
| CN117986386B (zh) * | 2024-02-06 | 2024-11-29 | 康立泰生物医药(青岛)有限公司 | 重组人白细胞介素-35及其制备方法和应用 |
| US20260035414A1 (en) * | 2024-08-01 | 2026-02-05 | Twilight Bioscience, Inc. | Herv-k (hml-2) env analog fusion proteins for antigen specific immunotherapy and methods of use |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE196297T1 (de) * | 1994-05-18 | 2000-09-15 | Synthetic Peptides Inc | Heterodimere trägerzusammensetzung von immunogenen polypeptiden und verfahren zu deren verwendung |
| IT1274350B (it) * | 1994-12-06 | 1997-07-17 | Angeletti P Ist Richerche Bio | Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130 |
| ATE295887T1 (de) | 1996-02-20 | 2005-06-15 | Applied Research Systems | Heterodimerebildende hybrid-proteine |
| EP1489100B1 (en) * | 1997-12-08 | 2016-06-15 | Merck Patent GmbH | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
| SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| JP4793971B2 (ja) * | 1999-08-09 | 2011-10-12 | メルク パテント ゲーエムベーハー | 複合サイトカイン−抗体複合体 |
| ES2381650T3 (es) * | 2000-08-08 | 2012-05-30 | Zymogenetics, Inc. | Receptores de citoquinas Zcytor11 solubles |
| ATE498633T1 (de) * | 2004-07-09 | 2011-03-15 | Variety Children S Hospital D B A Miami Children S Hospital | Materialien und verfahren zur stimulierung des immunsystems |
| EP2072527A1 (en) * | 2007-12-21 | 2009-06-24 | Altonabiotec AG | Fusion polypeptides comprising a SHBG dimerization component and uses thereof |
| KR20120108967A (ko) * | 2009-09-16 | 2012-10-05 | 제넨테크, 인크. | 코일드 코일 및/또는 테더 함유 단백질 복합체 및 그의 용도 |
| CN102958942A (zh) | 2009-12-29 | 2013-03-06 | 新兴产品开发西雅图有限公司 | 异二聚体结合蛋白及其应用 |
| EP4012714A1 (en) * | 2010-03-23 | 2022-06-15 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
| UY35148A (es) * | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| CA2902739C (en) * | 2013-03-15 | 2022-11-22 | Xencor, Inc. | Heterodimeric proteins |
| US10017545B2 (en) * | 2013-06-03 | 2018-07-10 | University Of Maryland, College Park | Compositions and vaccines comprising vesicles and methods of using the same |
| WO2017019623A2 (en) * | 2015-07-26 | 2017-02-02 | Molecular Templates, Inc. | Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes |
| HK1243629A1 (zh) | 2014-09-17 | 2018-07-20 | 基因泰克公司 | 包含抗her2抗体和吡咯并苯并二氮杂䓬的免疫缀合物 |
| CN104403004B (zh) * | 2014-11-24 | 2017-10-13 | 苏州丁孚靶点生物技术有限公司 | 抗体‑干扰素异二聚体的制备和用途 |
| CA2978186A1 (en) * | 2015-03-05 | 2016-09-09 | Fred Hutchinson Cancer Research Center | Immunomodulatory fusion proteins and uses thereof |
| RU2766200C1 (ru) | 2015-10-01 | 2022-02-09 | Хит Байолоджикс, Инк. | Композиции и способы для соединения внеклеточных доменов типа i и типа ii в качестве гетерологичных химерных белков |
| US10954301B2 (en) | 2015-12-14 | 2021-03-23 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof |
| CN118307682A (zh) * | 2016-09-27 | 2024-07-09 | 埃皮辛特瑞柯斯公司 | 免疫调节性融合蛋白 |
| US12447213B2 (en) * | 2016-10-07 | 2025-10-21 | The Broad Institute, Inc. | Modulation of novel immune checkpoint targets |
| MX2019009812A (es) * | 2017-02-27 | 2019-10-14 | Shattuck Labs Inc | Proteinas quimericas basadas en tigit y light. |
| KR20210025054A (ko) * | 2018-06-21 | 2021-03-08 | 샤턱 랩스 인코포레이티드 | 이형이량체 단백질 및 이의 용도 |
| US11098093B2 (en) * | 2019-01-07 | 2021-08-24 | Shattuck Labs, Inc. | Heterodimeric proteins for modulating gamma delta T cells |
| AU2020340424A1 (en) * | 2019-08-30 | 2022-03-31 | Shattuck Labs, Inc. | Chimeric proteins in autoimmunity |
-
2019
- 2019-06-21 KR KR1020217001659A patent/KR20210025054A/ko not_active Ceased
- 2019-06-21 EP EP19823119.3A patent/EP3810172A4/en not_active Withdrawn
- 2019-06-21 CA CA3103975A patent/CA3103975A1/en active Pending
- 2019-06-21 BR BR112020026112-2A patent/BR112020026112A2/pt unknown
- 2019-06-21 CN CN201980053803.4A patent/CN112566650A/zh active Pending
- 2019-06-21 AU AU2019290192A patent/AU2019290192A1/en not_active Abandoned
- 2019-06-21 JP JP2020571400A patent/JP7439372B2/ja active Active
- 2019-06-21 MX MX2020014031A patent/MX2020014031A/es unknown
- 2019-06-21 WO PCT/US2019/038451 patent/WO2019246508A1/en not_active Ceased
- 2019-09-16 US US16/571,853 patent/US10995127B2/en active Active
-
2021
- 2021-03-24 US US17/211,180 patent/US11780897B2/en active Active
-
2023
- 2023-01-17 US US18/155,218 patent/US20230220030A1/en not_active Abandoned
- 2023-06-15 JP JP2023098823A patent/JP7452932B2/ja active Active
-
2024
- 2024-03-04 JP JP2024032407A patent/JP2024057087A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7452932B2 (ja) | 2024-03-19 |
| WO2019246508A1 (en) | 2019-12-26 |
| AU2019290192A1 (en) | 2021-01-07 |
| JP2021527700A (ja) | 2021-10-14 |
| JP2024057087A (ja) | 2024-04-23 |
| CA3103975A1 (en) | 2019-12-26 |
| JP2023116718A (ja) | 2023-08-22 |
| CN112566650A (zh) | 2021-03-26 |
| US10995127B2 (en) | 2021-05-04 |
| EP3810172A4 (en) | 2022-04-20 |
| US20200079831A1 (en) | 2020-03-12 |
| EP3810172A1 (en) | 2021-04-28 |
| KR20210025054A (ko) | 2021-03-08 |
| US11780897B2 (en) | 2023-10-10 |
| BR112020026112A2 (pt) | 2021-04-06 |
| US20230220030A1 (en) | 2023-07-13 |
| US20210214409A1 (en) | 2021-07-15 |
| JP7439372B2 (ja) | 2024-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020014031A (es) | Proteinas heterodimericas y usos de las mismas. | |
| ZA201905488B (en) | Tigit- and light-based chimeric proteins | |
| PH12018500694A1 (en) | Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins | |
| PH12020500671A1 (en) | Antibodies specific for gucy2c and uses thereof | |
| MY203971A (en) | Anti-lag-3 antibodies and compositions | |
| PH12017501483A1 (en) | Bicyclic heterocycles as fgfr4 inhibitors | |
| WO2018190719A3 (en) | Anti-sirp alpha antibodies | |
| MX2022007140A (es) | Terapias combinadas dirigidas a proteina 1 de muerte celular programada (pd-1), proteina 3 de dominio de mucina y dominio inmunoglobulina de los linfocitos t (tim-3), y gen de activacion de linfocitos 3 (lag-3). | |
| PH12020550051A1 (en) | Glp-1 compositions and uses thereof | |
| CL2018003582A1 (es) | Composiciones para modular la expresión de c9orf72 (divisional solicitud 201702567) | |
| CR20200114A (es) | Compuestos que contienen pirazolopirimidinona y sus usos | |
| EA201891268A1 (ru) | Соединения, которые можно применять в качестве ингибиторов киназы | |
| WO2017134302A3 (en) | Targeted therapeutic agents and uses thereof | |
| PH12016501107B1 (en) | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology | |
| EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
| MX2022008523A (es) | Compuestos que interactuan con glicanos y metodos de uso. | |
| MX2020006365A (es) | Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14). | |
| PH12019501872A1 (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof | |
| PH12021551475A1 (en) | Heterodimeric proteins for modulating gamma delta t cells | |
| SG10201805646WA (en) | Angiopoietin-like 4 antibodies and methods of use | |
| MX2020000636A (es) | Proteinas sinteticas y usos terapeuticos de las mismas. | |
| TW201613977A (en) | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use | |
| MX2021002286A (es) | Terapias de combinacion. | |
| MX2024005649A (es) | Proteinas quimericas basadas en sirp1a y cd40l. | |
| MX2019009293A (es) | Compuestos, composiciones y usos de los mismos para la mejoria de trastornos oseos. |